Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
McKesson
Merck
Baxter

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,709,867

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,709,867
Title: Transgenic turfgrasses which signal exposure to chemicals and stress conditions
Abstract:Transgenic grass plants which exhibit a color different from the color exhibited by the corresponding non-transgenic grass plants under conditions of stress are provided Examples of such conditions include, but are not limited to, lack of fertilizer, lack of water, and attack by insects or pathogens. The genome of the transgenic grass plant comprises a transgene comprising a nucleic acid which encodes one or more regulators of anthocyanin biosynthesis, and an inducible promoter which is responsive to a stress condition, such as for example, nutrient deprivation, water deprivation, and attack by a pathogen.
Inventor(s): Grotewold; Erich (Columbus, OH)
Assignee: The Ohio State University Research Foundation (Columbus, OH)
Application Number:10/044,300
Patent Claims:1. A transgenic grass plant whose color phenotype changes to signal its exposure to a chemical or stress conditions, the transgenic grass plant comprising a transgene comprising: a) an exogenous anthocyanin regulatory gene; and b) an inducible promoter for regulating transcription of said anthocyanin regulatory gene, said promoter being operably linked to said anthocyanin regulatory gene, wherein the promoter is induced when the transgenic grass plant is exposed to a chemical or stress conditions, and wherein a change in color phenotype of the transgenic grass plant signals response of the transgenic grass plant to a chemical or stress conditions.

2. The transgenic grass plant of claim 1 wherein the promoter is a stress inducible promoter.

3. The transgenic grass plant of claim 2 wherein the stress inducible promoter is responsive to lack of fertilizer, lack of water, or infection with a pathogen.

4. The transgenic grass plant of claim 1 wherein the promoter is selected from the group consisting of the maize rab28 gene promoter, the maize rab17 gene promoter, the maize Ivr2 gene promoter, and the hydroxyproline-rich glycoprotein gene promoter.

5. The transgenic grass plant of claim 1 wherein the promoter is a chemical inducible promoter.

6. The transgenic grass plant of claim 1 wherein the chemical inducible promoter is responsive to a steroid or estradiol.

7. The transgenic grass plant of claim 1 wherein the grass is a turfgrass.

8. The transgenic grass plant of claim 1 wherein the turfgrass is selected from the group consisting of Tall fescue, Kentucky bluegrass, Perennial ryegrass, Creeping bentgrass, Bermuda grass, and Zoysia grass.

9. The transgenic grass plant of claim 1 wherein the anthocyanin regulatory gene is selected from the group consisting of a maize R gene, a combination of a maize C1 gene and a maize R gene, and a DNA construct encoding a chimeric CRC protein.

10. A nucleic acid construct comprising: a) an anthocyanin regulatory gene selected from the group consisting of an R gene, a combinations of a C1 gene and an R gene, and a DNA construct encoding chimeric CRC protein; and b) a stress inducible promoter operably linked to the anthocyanin regulatory gene, wherein the stress inducible promoter is responsive to stress conditions selected from the group consisting of lack of fertilizer, lack of water, and infection with a pathogen.

11. The nucleic acid construct of claim 10, wherein the inducible promoter is selected from the group consisting of the maize rab28 gene promoter, the maize rab17 gene promoter, to maize Ivr2 gene promoter, and the hydroxyproline-rich glycoprotein gene promoter.

12. The nucleic acid construct of claim 10, further comprising one or more of the sequences selected from the group consisting of a leader sequence, intron sequence, transcription terminator, and a polyadenylation site.

13. The nucleic acid construct of claim 10, further comprising one or more of the sequences selected from the group consisting of a marker gene sequence, a selectable gene sequence and a T-DNA sequence.

14. A method for making a transgenic grass plant which exhibits a color change in response to its exposure to a chemical or stress conditions, comprising: a) introducing a nucleic acid construct into a plant cell or protoplast, said construct comprising i.) an exogenous anthocyanin regulatory gene; and ii.) an inducible promoter for regulating transcription of said anthocyanin regulatory gene, said promoter being operably linked to said anthocyanin regulatory gene, b) regenerating a transgenic grass plant from said plant cell or protoplast containing said nucleic acid construct, and c) exposing the transgenic grass plant to a chemical or stress condition,

wherein said chemical or stress condition induces said promoter, and causes a change in color of the transgenic grass plant, which signals the response of the transgenic grass plant to said chemical or stress conditions.

15. The method of claim 14 wherein the plant cell used for introduction of the nucleic acid construct is from a grass plant selected from the group consisting of Tall fescue, Kentucky bluegrass, Perennial ryegrass, Creeping bentgrass, Bermuda grass and Zoysia grass.

16. The method of claim 14 wherein the promoter is selected from the group consisting of a stress inducible promoter and a chemical inducible promoter.

17. A seed of any generation of the transgenic grass plant of claim 1, wherein said seed comprises said transgene.

18. The method of claim 14, wherein the nucleic acid construct further comprises a sequence selected from the group consisting of a leader sequence, intron sequence, transcription terminator, polyadenylation site, and combinations thereof.

19. The method of claim 14, wherein the nucleic acid construct further comprises a marker gene sequence, a selectable gene sequence, T-DNA sequence, or combinations thereof.

20. The method of claim 14, wherein said anthocyanin regulatory gene is selected from the group consisting of an R gene, a combination of a C1 gene and an R gene, and a DNA construct encoding a chimeric CRC protein.

Details for Patent 6,709,867

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Ohio State University Research Foundation (Columbus, OH) 2020-10-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Ohio State University Research Foundation (Columbus, OH) 2020-10-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Ohio State University Research Foundation (Columbus, OH) 2020-10-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Johnson and Johnson
Medtronic
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.